RNA Disease Diagnostics Further Strengthens Executive Leadership with Appointment of John W. Erickson, Jr. as President

NEXT STORY
TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial
PREV STORY
Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Achaogen Stock Trading Halted Today

-- FDA Advisory Committee to Review Plazomicin for the Treatment of Adults with Complicated Urinary ...

author_avatar
NASDAQ Market News

Paratek Pharmaceuticals Hosting Investor Webinar with Corporate Updates and Key Opinion Leader and Patient Advocate Presentations on Non-Tuberculous Mycobacteria, M. abscessus

author_avatar
NASDAQ Market News

HOOKIPA Pharma Reports Second Quarter 2020 Financial Results and Provides a Corporate Update

author_avatar
NASDAQ Market News